Oli is a senior associate in our Cambridge office and is part of the Corporate Technology team.
Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.
We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releasevon mehreren Autoren
Advising Baseimmune on its £9 million funding round
von Ross McNaughton und Oli Denne
Advising on Mission Zero Technologies on its £21.8 million Series A funding
von Ross McNaughton und Oli Denne
von mehreren Autoren
von mehreren Autoren
von Dr. Amir-Said Ghassabeh und Dr. David Klein, LL.M. (Univ. of Washington), CIPP/E
von mehreren Autoren
von mehreren Autoren
von Nicholas Vollers und Adrian Toutoungi
von mehreren Autoren
von Charlie Adams und Adrian Toutoungi